Servier finalizes acquisition of Shire’s oncology branch

03-Sep-2018 - Servier announced that it has finalized the previously announced acquisition of Shire’s oncology branch after obtaining regulatory clearance. The 2.4 billion dollar transaction will enable Servier to establish a direct commercial presence in the United States and strengthen its oncology drug ...

Shire rejects Takeda's acquisition offers

20-Apr-2018 - Shire notes the announcement made by Takeda. The Board of Shire confirms that it has received three conditional proposals from Takeda regarding a possible offer for the Company, on 29 March 2018 (the “First Proposal”), 11 April 2018 (the “Second Proposal”) and 13 April 2018 (the “Third ...

Takeda interested in Shire

29-Mar-2018 - Takeda confirms that it is considering making an approach to Shire regarding a possible offer for the company. Takeda’s consideration of such an offer is at a preliminary and exploratory stage and no approach has been made to the Board of Shire. There can be no certainty that an approach, if ...

Shire to combine with Baxalta

Combination creates global biotechnology company

13-Jan-2016 - Shire plc and Baxalta Incorporated announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta. Under the agreement, Baxalta shareholders will receive $18.00 in cash and 0.1482 Shire ADS per Baxalta share. Based on Shire's ...

Ethris announces research based alliance on SNIM modified RNA with Shire

09-Jan-2013 - Ethris GmbH and Shire announce the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics. Many devastating human diseases are the result of an inability of the body’s cells to make specific proteins that have an essential function ...

Heptares grants Shire an exclusive worldwide license to develop and commercialise drug candidates for CNS disorders

22-Mar-2012 - Heptares Therapeutics announced that an operating company of Shire plc has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the ...

arGEN-X enters into therapeutic antibody alliance with Shire

02-Mar-2012 - arGEN-X announced that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire. Using its SIMPLE Antibody™ discovery technology, arGEN-X will isolate and characterize human antibodies against the targets that Shire has ...

Shire Presents Positive Data from Fabry and Gaucher Disease Studies that Continue to Support Patient Switches to REPLAGAL and VPRIV

01-Sep-2011 - Shire plc announced positive data from several studies designed to evaluate the safety of switching to REPLAGAL (agalsidase alfa) from Fabrazyme® (agalsidase beta) and the long-term safety and benefits of switching to VPRIV (velaglucerase alfa) from Cerezyme® (imiglucerase). Study results are ...

Shire Announces European Approval of VPRIV (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease

30-Aug-2010 - Shire plc announced that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease. VPRIV has been authorized as an orphan medicine through the ...

Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease

17-Jul-2009 - Shire plc announces it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type I Gaucher disease. Shire is working with the FDA to determine subsequent steps and timing for ...